PTGX FDA approves MIMRYLO for PV
PTGX says the FDA approved MIMRYLO for PV, positioning it as erythrocytosis-specific therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
PTGX FDA approves MIMRYLO for erythrocytosis in PV
PTGX says the FDA has approved MIMRYLO for erythrocytosis in PV, described as first-in-class with a broadly labeled therapy.